
CCRN Stock Forecast & Price Target
CCRN Analyst Ratings
Bulls say
Cross Country Healthcare has shown stabilization in gross margin at 20.0%, maintaining this level from the previous quarter and exceeding prior estimates. The company is the subject of an acquisition agreement with Aya Healthcare, offering $18.61 per share in cash, representing a substantial 67% premium over its previous closing price. Additionally, the anticipated timeline for the transaction has shifted to the second half of 2025, providing an extended period for value realization for shareholders.
Bears say
Cross Country Healthcare's financial performance has shown significant deterioration, with Q1 2025 Adjusted EBITDA declining 44% year-over-year to $8.6 million, despite surpassing a prior estimate of $6.6 million. Revenue for the same period fell to $293.4 million, which not only missed estimates but also marked a 23% year-over-year decline, attributed to ongoing weak demand in the healthcare travel staffing sector. Furthermore, the company has revised its 2025 revenue forecast downward to $1.166 billion, representing a 13.3% year-over-year decrease from the previously projected $1.255 billion.
This aggregate rating is based on analysts' research of Cross Country Healthcare and is not a guaranteed prediction by Public.com or investment advice.
CCRN Analyst Forecast & Price Prediction
Start investing in CCRN
Order type
Buy in
Order amount
Est. shares
0 shares